236 related articles for article (PubMed ID: 22035336)
1. Review: insights gained from modelling high-grade glioma in the mouse.
Rankin SL; Zhu G; Baker SJ
Neuropathol Appl Neurobiol; 2012 Jun; 38(3):254-70. PubMed ID: 22035336
[TBL] [Abstract][Full Text] [Related]
2. Review: low-grade gliomas as neurodevelopmental disorders: insights from mouse models of neurofibromatosis-1.
Thangarajh M; Gutmann DH
Neuropathol Appl Neurobiol; 2012 Jun; 38(3):241-53. PubMed ID: 22035280
[TBL] [Abstract][Full Text] [Related]
3. Cell of origin of glioma: biological and clinical implications.
Alcantara Llaguno SR; Parada LF
Br J Cancer; 2016 Dec; 115(12):1445-1450. PubMed ID: 27832665
[TBL] [Abstract][Full Text] [Related]
4. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.
Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH
Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381
[TBL] [Abstract][Full Text] [Related]
5. Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis.
Erson-Omay EZ; Çağlayan AO; Schultz N; Weinhold N; Omay SB; Özduman K; Köksal Y; Li J; Serin Harmancı A; Clark V; Carrión-Grant G; Baranoski J; Çağlar C; Barak T; Coşkun S; Baran B; Köse D; Sun J; Bakırcıoğlu M; Moliterno Günel J; Pamir MN; Mishra-Gorur K; Bilguvar K; Yasuno K; Vortmeyer A; Huttner AJ; Sander C; Günel M
Neuro Oncol; 2015 Oct; 17(10):1356-64. PubMed ID: 25740784
[TBL] [Abstract][Full Text] [Related]
6. Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma.
Jones C; Baker SJ
Nat Rev Cancer; 2014 Oct; 14(10):. PubMed ID: 25230881
[TBL] [Abstract][Full Text] [Related]
7. Gliomagenesis: genetic alterations and mouse models.
Holland EC
Nat Rev Genet; 2001 Feb; 2(2):120-9. PubMed ID: 11253051
[TBL] [Abstract][Full Text] [Related]
8. The genetic signatures of pediatric high-grade glioma: no longer a one-act play.
Diaz AK; Baker SJ
Semin Radiat Oncol; 2014 Oct; 24(4):240-7. PubMed ID: 25219808
[TBL] [Abstract][Full Text] [Related]
9. Mutations in chromatin machinery and pediatric high-grade glioma.
Lulla RR; Saratsis AM; Hashizume R
Sci Adv; 2016 Mar; 2(3):e1501354. PubMed ID: 27034984
[TBL] [Abstract][Full Text] [Related]
10. Comparison of
Unterrainer M; Fleischmann DF; Diekmann C; Vomacka L; Lindner S; Vettermann F; Brendel M; Wenter V; Ertl-Wagner B; Herms J; Wetzel C; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):580-590. PubMed ID: 30244386
[TBL] [Abstract][Full Text] [Related]
11. Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas.
Herting CJ; Chen Z; Pitter KL; Szulzewsky F; Kaffes I; Kaluzova M; Park JC; Cimino PJ; Brennan C; Wang B; Hambardzumyan D
Glia; 2017 Dec; 65(12):1914-1926. PubMed ID: 28836293
[TBL] [Abstract][Full Text] [Related]
12. Mouse models of glioma.
Stylli SS; Luwor RB; Ware TM; Tan F; Kaye AH
J Clin Neurosci; 2015 Apr; 22(4):619-26. PubMed ID: 25698543
[TBL] [Abstract][Full Text] [Related]
13. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma.
Venkatesh HS; Tam LT; Woo PJ; Lennon J; Nagaraja S; Gillespie SM; Ni J; Duveau DY; Morris PJ; Zhao JJ; Thomas CJ; Monje M
Nature; 2017 Sep; 549(7673):533-537. PubMed ID: 28959975
[TBL] [Abstract][Full Text] [Related]
14. Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management.
Sturm D; Pfister SM; Jones DTW
J Clin Oncol; 2017 Jul; 35(21):2370-2377. PubMed ID: 28640698
[TBL] [Abstract][Full Text] [Related]
15. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease.
Paugh BS; Qu C; Jones C; Liu Z; Adamowicz-Brice M; Zhang J; Bax DA; Coyle B; Barrow J; Hargrave D; Lowe J; Gajjar A; Zhao W; Broniscer A; Ellison DW; Grundy RG; Baker SJ
J Clin Oncol; 2010 Jun; 28(18):3061-8. PubMed ID: 20479398
[TBL] [Abstract][Full Text] [Related]
16. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches.
Westphal M; Lamszus K
Nat Rev Neurosci; 2011 Aug; 12(9):495-508. PubMed ID: 21811295
[TBL] [Abstract][Full Text] [Related]
17. Cell of origin determines tumor phenotype in an oncogenic Ras/p53 knockout transgenic model of high-grade glioma.
Ghazi SO; Stark M; Zhao Z; Mobley BC; Munden A; Hover L; Abel TW
J Neuropathol Exp Neurol; 2012 Aug; 71(8):729-40. PubMed ID: 22805776
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of microRNA-210 in gliomas of variable cell origin and correlation between increased expression levels and disease progression in astrocytic tumours.
Lai N; Zhu H; Chen Y; Zhang S; Zhao X; Lin Y
Folia Neuropathol; 2014; 52(1):79-85. PubMed ID: 24729345
[TBL] [Abstract][Full Text] [Related]
19. Advances in Research of Adult Gliomas.
Finch A; Solomou G; Wykes V; Pohl U; Bardella C; Watts C
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477674
[TBL] [Abstract][Full Text] [Related]
20. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma.
Koschmann C; Zamler D; MacKay A; Robinson D; Wu YM; Doherty R; Marini B; Tran D; Garton H; Muraszko K; Robertson P; Leonard M; Zhao L; Bixby D; Peterson L; Camelo-Piragua S; Jones C; Mody R; Lowenstein PR; Castro MG
Oncotarget; 2016 Oct; 7(40):65696-65706. PubMed ID: 27582545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
